Payment overview · 2025
General Payments
$416.63
22 reported records · 7 companies
Healthcare provider profile · identity verified
Brittney W Berckman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TIFTON, GA · NPI 1114189230
Verified facts
What the public records show
CMS Open Payments records show Brittney W Berckman, MD received $416.63 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $179.54 | 43.1% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $100.12 | 24.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.57 | 18.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.67 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.84 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.72 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.17 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $416.63 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $149.66 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $100.12 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.57 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.29 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.88 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 271 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
163 | 41 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
271 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 93 |
| Omeprazole | Omeprazole | 331 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 314 | 84 |
| Losartan Potassium | Losartan Potassium | 309 | 82 |
| Montelukast Sodium | Montelukast Sodium | 295 | 74 |
| Mounjaro | Tirzepatide | 271 | 42 |
| Lisinopril | Lisinopril | 270 | 76 |
| Gabapentin | Gabapentin | 248 | 71 |
| Tramadol Hcl | Tramadol Hcl | 244 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 220 | 40 |
| Alprazolam | Alprazolam | 217 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 55 |
| Linzess | Linaclotide | 163 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 73 |
| Potassium Chloride | Potassium Chloride | 152 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 45 |
| Ozempic | Semaglutide | 142 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 37 |
| Furosemide | Furosemide | 141 | 53 |
| Carvedilol | Carvedilol | 137 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 118 | 43 |
| Metformin Hcl | Metformin Hcl | 114 | 30 |
| Trazodone Hcl | Trazodone Hcl | 114 | 26 |
| Pregabalin | Pregabalin | 111 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 31 |
| Meloxicam | Meloxicam | 103 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 97 | 35 |
| Famotidine | Famotidine | 85 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 20 |
| Sertraline Hcl | Sertraline Hcl | 81 | 23 |
| Eliquis | Apixaban | 80 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 23 |
| Glipizide Er | Glipizide | 78 | 20 |
| Metformin Hcl Er | Metformin Hcl | 76 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 15 |
| Memantine Hcl | Memantine Hcl | 74 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 22 |
| Simvastatin | Simvastatin | 70 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 68 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 25 |
| Synthroid | Levothyroxine Sodium | 65 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 19 |
| Buspirone Hcl | Buspirone Hcl | 58 | 20 |
| Lorazepam | Lorazepam | 57 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 14 |
| Temazepam | Temazepam | 54 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 44 |
| Diazepam | Diazepam | 52 | suppressed |
| Chlorthalidone | Chlorthalidone | 50 | 13 |
| Farxiga | Dapagliflozin Propanediol | 49 | 12 |
| Ondansetron Odt | Ondansetron | 47 | 16 |
| Allopurinol | Allopurinol | 46 | 16 |
| Meclizine Hcl | Meclizine Hcl | 46 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 14 |
| Methylprednisolone | Methylprednisolone | 45 | 33 |
| Myrbetriq | Mirabegron | 44 | 12 |
| Glipizide | Glipizide | 43 | 13 |
| Lubiprostone | Lubiprostone | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 11 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 36 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Prednisone | Prednisone | 35 | 19 |
| Promethazine Hcl | Promethazine Hcl | 33 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 26 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Nystatin | Nystatin | 28 | 19 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 20 |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 17 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 12 |
| Colchicine | Colchicine | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $416.63 · 22 records | Novo Nordisk Inc | MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error